Immunic Therapeutics is a clinical-stage biotech company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Immunic, Inc. is headquartered in New York. Its subsidiary, Immunic AG, is based in Graefelfing near Munich, Germany, where the company’s research and development activities are conducted. Additional subsidiaries are located in Halle/Saale, Germany, and Melbourne, Australia.

Immunic is developing three small molecule products: lead development program, IMU-838, is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. IMU-838 is in phase 2 clinical development for COVID-19, relapsing-remitting multiple sclerosis, ulcerative colitis and, in collaboration with the Mayo Clinic, primary sclerosing cholangitis.

Press releases

28. August 2019
Immunic AG Awarded Research Grant by German Federal Ministry of Education and Research in Support of the InnoMuNiCH Project
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that the German Federal Ministry of Education and Research has awarded its subsidiary, Immunic AG, a grant in the amount of up to EUR 653,535 (approximately USD 730,000) in support of the InnoMuNiCH (Innovations through Munich-Nippon Cooperation in Healthcare) project. The InnoMu
15. April 2019
High-Tech Gründerfonds portfolio company Immunic Therapeutics to trade on NASDAQ
Reverse takeover enables Immunic to secure US listing on world’s largest electronic stock exchange Existing Immunic investors invested a further EUR 26.7 million as part of NASDAQ listing Founded in Bavaria, Germany, in 2016, the biotech start-up develops novel treatments for chronic inflammatory diseases High-Tech Gründerfonds has been at Immunic’s side from the very beginning Immunic’s listing on the NASDAQ has been achieved through a reverse takeover, with the company slippin
27. September 2016
Immunic successfully closes 17.5 million Euro Series A financing round
Immunic AG (Immunic), a recently formed private start-up biotech company in Planegg-Martinsried near Munich, Germany, today announced that it has closed its Series A financing round totaling EUR 17.5 million of preferred stock financing. The financing round was led by Life Sciences Partners V Coöperatief U.A. (LSP, The Netherlands) and LifeCare Partners (LCP, Switzerland). Further participating investors were Bayern Kapital (Landshut, Germany), High-Tech Gründerfonds (HTGF, Bonn, Germany) and

Info & Contact

Jessica Breu


Lochhamer Schlag 21
82166 Graefelfing

In portfolio

10. Aug 2016